If we go back to early in the year the SP was at around $3.30 based on the anticipated FDA approval for aGVHD. Since then the focus has been, and rightly so, on remestemcel-L for COVID-19.
Given all the competition in this space, the main goal for MSB is to show efficacy of MSC’s(which we already know work for aGVHD). The reason, is that it will provide validation that MSC’s are effective on a ‘global scale’ and thrust MSB into the spotlight. The COVID opportunity may or may not generate significant revenues, if a competitor were to also be successful at a cheaper cost. The main game for MSB is the heart, back pain trial and soon to be approved Remestemcel-L for aGVHD. Not to mention any expanded uses e.g. Crohns Disease.
Don’t get me wrong COVID-19 is important, and a successful trial would push up the SP. What will move it exponentially higher from there, would be successful P3 outcomes, which are expected anytime now!
As stated before, the next few weeks and months are the most exciting of MSB’s existence.
GLTAH
Analysis of the EAP, page-926
-
- There are more pages in this discussion • 145 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.045(4.00%) |
Mkt cap ! $1.335B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.18 | $1.13 | $4.980M | 4.315M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 73090 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 27903 | 1 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |